Impact of maintenance rituximab in patients with de novo transformed indolent B cell lymphoma

Leuk Lymphoma. 2020 Dec;61(12):2985-2989. doi: 10.1080/10428194.2020.1789631. Epub 2020 Jul 6.

Affiliations

¹ Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
² Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

PMID: 32628087
DOI: 10.1080/10428194.2020.1789631

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural

MeSH terms

Antibodies, Monoclonal, Murine-Derived / therapeutic use
Antineoplastic Agents* / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Humans
Lymphoma, B-Cell* / drug therapy
Rituximab / therapeutic use

Substances

Antibodies, Monoclonal, Murine-Derived
Antineoplastic Agents
Rituximab